Revitalizing the Pharmaceutical Business PDF Download

Author: R. B. Smarta
Publisher:
ISBN: 9788170368403
Category : Drugs
Languages : en
Pages : 294

View

Book Description

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 030904491X
Category : Medical
Languages : en
Pages : 225

View

Book Description
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.

Author: John Lidstone
Publisher: Taylor & Francis
ISBN: 1351919768
Category : Business & Economics
Languages : en
Pages : 169

View

Book Description
Marketing in the pharmaceutical and healthcare sector requires a particular set of skills; its intricacies mean planning is an essential prerequisite. The marketing planning system described in this book has been designed to enable marketing and product executives to produce a plan which serves as a dynamic management tool which will help them to get from where they are now to where they want to be next year and thereafter. Now in its second edition, this bestselling book has become the standard text for all product managers, marketing managers and directors working in this demanding industry. John Lidstone and Janice MacLennan have updated the book to embrace best current practice. A new orientation to external analysis and a reworking of the application of SWOT analysis, along with fresh material on sales forecasting and strategy implementation, bring the book up to date with current thinking and industry trends. Marketing Planning for the Pharmaceutical Industry is based on real life experience built up over many years. Each chapter takes the reader through the sequential stages of planning so that by the end they will be able to produce a practical plan ready for implementation. It is the only book of this type which tailors marketing to those working in the sector and as such is a unique, invaluable and indispensable resource.

Author: Joey Reiman
Publisher: Rowman & Littlefield
ISBN: 1563524694
Category : Creative ability in business
Languages : en
Pages : 209

View

Book Description
Can one idea be worth a million dollars? Of course. But what is a million-dollar idea worth if it is poorly executed? In this ground-breaking, paradigm-shifting book, creative genius Joey Reiman presents a convincing argument for the value of raw ideas.

Author: Arthur G. Cook
Publisher: CRC Press
ISBN: 1317134109
Category : Business & Economics
Languages : en
Pages : 234

View

Book Description
Forecasting for the Pharmaceutical Industry is a definitive guide for forecasters as well as the multitude of decision makers and executives who rely on forecasts in their decision making. In virtually every decision, a pharmaceutical executive considers some type of forecast. This process of predicting the future is crucial to many aspects of the company - from next month's production schedule, to market estimates for drugs in the next decade. The pharmaceutical forecaster needs to strike a delicate balance between over-engineering the forecast - including rafts of data and complex ’black box’ equations that few stakeholders understand and even fewer buy into - and an overly simplistic approach that relies too heavily on anecdotal information and opinion. Arthur G. Cook's highly pragmatic guide explains the basis of a successful balanced forecast for products in development as well as currently marketed products. The author explores the pharmaceutical forecasting process; the varied tools and methods for new product and in-market forecasting; how they can be used to communicate market dynamics to the various stakeholders; and the strengths and weaknesses of different forecast approaches. The text is liberally illustrated with tables, diagrams and examples. The final extended case study provides the reader with an opportunity to test out their knowledge. The second edition has been updated throughout and includes a brand new chapter focusing on specialized topics such as forecasting for orphan drugs and biosimilars.

Author: David Herzberg
Publisher: University of Chicago Press
ISBN: 022673191X
Category : History
Languages : en
Pages : 372

View

Book Description
The contemporary opioid crisis is widely seen as new and unprecedented. Not so. It is merely the latest in a long series of drug crises stretching back over a century. In White Market Drugs, David Herzberg explores these crises and the drugs that fueled them, from Bayer’s Heroin to Purdue’s OxyContin and all the drugs in between: barbiturate “goof balls,” amphetamine “thrill pills,” the “love drug” Quaalude, and more. As Herzberg argues, the vast majority of American experiences with drugs and addiction have taken place within what he calls “white markets,” where legal drugs called medicines are sold to a largely white clientele. These markets are widely acknowledged but no one has explained how they became so central to the medical system in a nation famous for its “drug wars”—until now. Drawing from federal, state, industry, and medical archives alongside a wealth of published sources, Herzberg re-connects America’s divided drug history, telling the whole story for the first time. He reveals that the driving question for policymakers has never been how to prohibit the use of addictive drugs, but how to ensure their availability in medical contexts, where profitability often outweighs public safety. Access to white markets was thus a double-edged sword for socially privileged consumers, even as communities of color faced exclusion and punitive drug prohibition. To counter this no-win setup, Herzberg advocates for a consumer protection approach that robustly regulates all drug markets to minimize risks while maintaining safe, reliable access (and treatment) for people with addiction. Accomplishing this requires rethinking a drug/medicine divide born a century ago that, unlike most policies of that racially segregated era, has somehow survived relatively unscathed into the twenty-first century. By showing how the twenty-first-century opioid crisis is only the most recent in a long history of similar crises of addiction to pharmaceuticals, Herzberg forces us to rethink our most basic ideas about drug policy and addiction itself—ideas that have been failing us catastrophically for over a century.

Author: ISLAMIC FINANCE RESEARCH
Publisher: ISLAMIC FINANCE RESEARCH
ISBN:
Category : Business & Economics
Languages : en
Pages : 20

View

Book Description
Why include APIs industries stock in your portfolio? Active Pharma Ingredients (APIs) are the raw materials that go into manufacturing medicines. China is the world's largest API manufacturer, followed by the US and India. However, the gap between them is a little. The significant advantage for India is the potential growth opportunity. India's API industry estimates Rs.79,800 crore as of 2020, but it is likely to grow at 8.57% CAGR over the next five years to Rs.131,000 crore by 2026. On the other hand, the Chinese API industry will grow by just 6.5% in the same period. These refer to the merchant API business, which is non-exclusive. When is the best time to put money into this industry? In recent times, three factors shifted the game in favour of Indian API manufacturers: Most countries believe that China did play a role in suppressing details of the pandemic and hence would prefer to diversify from their overt API dependence on China. The Chinese government has clamped down heavily on environmental lapses, and the API industry has come in for a lot of flak, disrupting supply chains. That opened a new window of opportunity for India. To promote APIs, the government of India also offered Product linked incentives (PLI) scheme. Here is a look at some critical API names in India and thematic investment ideas. How are APIs companies regulated? Heralding these regulatory changes, the CDSCO claimed8 that it had initiated various measures in the last two years to streamline the regulatory procedures by relaxing, rationalizing, and modifying the existing provisions of the DCR, which has resulted in accelerating the regulatory approvals without compromising the safety, quality, and performance of medical products. A separate, simplified, and extensive New Drugs and Clinical Trials (CT) Rules under the Drugs and Cosmetics Act, 1940 (DCA) that will codify all amendments to date is in the planning stages. In its efforts toward digitization and implementation of the e-governance scheme, MoH launched its online licensing system called SUGAM, nine which remains continuously expanded in a phased manner, giving impetus to the government's "Make in India" initiative; emphasis remains placed on ensuring the safety, efficacy, and quality of drugs manufactured in India by requiring the submission of stable data and compliance with GMP/GLP practices. Additionally, there are deliberations for plugging the gaps in a drug sale, including internet sales10 and OTCs. What is the future of this industry? The pharmaceutical industry has recently entered unexplored territory with pending approvals of blockbuster or generic drugs whose production and supply can only run seamlessly based on APIs. These biologically active substances remain inserted into excipients, which serve as the vehicle for delivery to the patient. The formulation of APIs remains contracted to develop countries due to their low production costs and ability to scale production according to customization. The global API market will reach a purported valuation of $215,125.4 million by 2023. Al Zayd Corp www.alzaydcorp.com Islamic Finance Research www.ifr.world Self-Published Research Magazine Author: Zayd Iqbal Haji Copyright © 2020 Al Zayd Corp | Islamic Finance Research All Rights Reserved. Disclaimer: This investment research report is not an acquisition recommendation and is not misinterpreted for investment consultation as it is a piece of information about the above company. All design content is copyrighted, and references are from the company's annual and RBI reports. Note: Analysts certify that all views expressed in the magazine accurately reflect the theories from the company's annual reports. Moreover, not a part of the investment recommendation or will not be directly or indirectly related to specific recommendations or views expressed in this report.

Author: Amit Kumar Nayak
Publisher: Academic Press
ISBN: 0128203005
Category : Medical
Languages : en
Pages : 572

View

Book Description
Advances and Challenges in Pharmaceutical Technology: Materials, Process Development and Drug Delivery Strategies examines recent advancements in pharmaceutical technology. The book discusses common formulation strategies, including the use of tools for statistical formulation optimization, Quality by design (QbD), process analytical technology, and the uses of various pharmaceutical biomaterials, including natural polymers, synthetic polymers, modified natural polymers, bioceramics, and other bioinorganics. In addition, the book covers rapid advancements in the field by providing a thorough understanding of pharmaceutical processes, formulation developments, explorations, and exploitation of various pharmaceutical biomaterials to formulate pharmaceutical dosage forms. Provides extensive information and analysis on recent advancements in the field of pharmaceutical technology Includes contributions from global leaders and experts in academia, industry and regulatory agencies Uses high quality illustrations, flow charts and tables to explain concepts and text to readers, along with practical examples and research case studies

Author: Ariel Fernandez
Publisher: Springer Science & Business Media
ISBN: 3642117929
Category : Technology & Engineering
Languages : en
Pages : 230

View

Book Description
In spite of the enticing promises of the post-genomic era, the pharmaceutical world is in a state of disarray. Drug discovery seems now riskier and more uncertain than ever. Thus, projects get routinely terminated in mid-stage clinical trials, new targets are getting harder to find, and successful therapeutic agents are often recalled as unanticipated side effects are discovered. Exploiting the huge output of genomic studies to make safer drugs has proven to be much more difficult than anticipated. More than ever, the lead in the pharmaceutical industry depends on the ability to harness innovative research, and this type of innovation can only come from one source: fundamental knowledge. This book squarely addresses this crucial problem since it introduces fundamental discoveries in basic biomolecular research that hold potential to broaden the technological base of the pharmaceutical industry. The book takes a fresh and fundamental look at the problem of how to design an effective drug with controlled specificity. Since the novel transformative concepts are unfamiliar to most practitioners, the first part of this book explains matters very carefully starting from a fairly elementary physico-chemical level. The second part of the book is devoted to practical applications, aiming at nothing less than a paradigm shift in drug design. This book is addressed to scientists working at the cutting edge of research in the pharmaceutical industry, but the material is at the same time accessible to senior undergraduates or graduate students interested in drug discovery and molecular design.

Author: Joan Fitzgerald
Publisher: SAGE Publications
ISBN: 1452264279
Category : Science
Languages : en
Pages : 281

View

Book Description
In Economic Revitalization: Cases and Strategies for City and Suburb Fitzgerald and Leigh answer the need for a text that incorporates social justice and sustainability into how we think about and practice economic development. It is one of the first to talk about how revitalization strategies are implemented in both cities and suburbs, particularly inner-ring suburbs that are experiencing decline previously associated only with inner-city neighborhoods. After setting the context with a brief history of economic development practice and its shortcomings, Fitzgerald and Leigh focus on six economic development strategies: sectoral strategies, Brownfield redevelopment, industrial retention, commercial revitalization, industrial and office property reuse, and workforce development.